FDA ALERT: Efficacy Issue Identified in Some Patients Taking Pembrolizumab or Atezolizumab as Monotherapy to Treat Advanced Urothelial Cancer - Petros Grivas

(Length of Discussion: 16 min)

Petros Grivas and Alicia Morgans discuss the late-breaking FDA Alert announcing the label changes for Pembrolizumab and Atezolizumab as Monotherapy to Treat Urothelial Cancer with Low Expression of PD-L1.

Biographies:

Petros Grivas MD, Ph.D. a medical oncologist at Seattle Cancer Care Alliance with expertise in genitourinary cancers such as bladder cancer, prostate cancer, and testis cancer.  He is the Clinical Director, of the Genitourinary Cancers Program at the University of Washington Medicine and an Associate Professor of the Department of Medicine, Division of Oncology at the University of Washington School of Medicine.

Alicia Morgans, MD, MPH